Resmed 1QFY17 – Get Ready to Buy

Resmed (RMD.ASX) reports first quarter FY17 results on the 26th of October. The result is likely to meet or exceed market expectations.

RMD is forecast to deliver 10%+ in EPS growth across the next few years. The recent acquisition of Brightree, Inova and Curative Medical will underpin both revenue and future profit growth, within an industry sector where demand continues to grow.

You’re not a member!  Trial today

rmd

 

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.